The Clinical Prognostic Value of LRG1 in Esophageal Squamous Cell Carcinoma / Yuanyuan Wang, Qian Xing, Xue Chen, Jianbo Wang, Shanghui Guan, Xuan Chen, Peng Sun, Mingxia Wang, Yufeng Cheng
Background: Leucine-rich-alpha-2-glycoprotein1 (LRG1) is a new oncogene-related gene, which has been proven important for the development and poor prognosis of human cancers. However, whether it participates in esophageal squamous cell carcinoma (ESCC) progression remains unclear. Objective: To investigate the expression level and functional influence of LRG1 in ESCC. Methods: The expression of LRG1 was evaluated on the mRNA and protein level in ESCC patients. Then, correlation of LRG1 expression with clinicpathological variables was analyzed in ESCC. Besides, to clarify the biological function of LRG1, Eca109 and KYSE150 cells were transfected with LRG1 shRNA, the cell viability, clonal efficiency, apoptosis and invasion assays in vitro were performed. Results: LRG1 was significantly over-expressed in ESCC and related to deeper invasion depth (T stage) and distal metastasis (M stage). Kaplan-Meier analysis indicated that LRG1 up-regulation in ESCC was closely correlated to worse clinical survival (overall survival and progression-free survival), all P<0.001. LRG1 was confirmed to be an independent poor premonitory indicator for clinical outcomes in ESCC through the univariate and multivariate analyses. Down-regulation of LRG1 in ESCC cells markedly suppressed cell proliferation and invasion, stimulated apoptosis (all p <0.01). Conclusion: LRG1 might play a significant role in the progression of ESCC, and could be served as a promising prognostic prediction for ESCC patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Current cancer drug targets - 19(2019), 9, Seite 756- |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, YuanyuanYuanyuan [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (8 p) |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
KFL00101658X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL00101658X | ||
| 003 | DE-627 | ||
| 005 | 20231128165843.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210608s2019 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)KFL00101658X | ||
| 035 | |a (KFL)prod_DARH_.5B70389FFFCFB77A63593658382BDE3DDBC01321 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Wang, YuanyuanYuanyuan |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Clinical Prognostic Value of LRG1 in Esophageal Squamous Cell Carcinoma |c Yuanyuan Wang, Qian Xing, Xue Chen, Jianbo Wang, Shanghui Guan, Xuan Chen, Peng Sun, Mingxia Wang, Yufeng Cheng |
| 264 | 1 | |c 2019 | |
| 300 | |a 1 Online-Ressource (8 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background: Leucine-rich-alpha-2-glycoprotein1 (LRG1) is a new oncogene-related gene, which has been proven important for the development and poor prognosis of human cancers. However, whether it participates in esophageal squamous cell carcinoma (ESCC) progression remains unclear. Objective: To investigate the expression level and functional influence of LRG1 in ESCC. Methods: The expression of LRG1 was evaluated on the mRNA and protein level in ESCC patients. Then, correlation of LRG1 expression with clinicpathological variables was analyzed in ESCC. Besides, to clarify the biological function of LRG1, Eca109 and KYSE150 cells were transfected with LRG1 shRNA, the cell viability, clonal efficiency, apoptosis and invasion assays in vitro were performed. Results: LRG1 was significantly over-expressed in ESCC and related to deeper invasion depth (T stage) and distal metastasis (M stage). Kaplan-Meier analysis indicated that LRG1 up-regulation in ESCC was closely correlated to worse clinical survival (overall survival and progression-free survival), all P<0.001. LRG1 was confirmed to be an independent poor premonitory indicator for clinical outcomes in ESCC through the univariate and multivariate analyses. Down-regulation of LRG1 in ESCC cells markedly suppressed cell proliferation and invasion, stimulated apoptosis (all p <0.01). Conclusion: LRG1 might play a significant role in the progression of ESCC, and could be served as a promising prognostic prediction for ESCC patients | ||
| 700 | 1 | |a Xing, Qian |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Xue |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jianbo |e verfasserin |4 aut | |
| 700 | 1 | |a Guan, Shanghui |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Xuan |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Peng |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Mingxia |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Yufeng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current cancer drug targets |d Hilversum [u.a.] : Bentham Science Publ., 2001 |g 19(2019), 9, Seite 756- |h Online-Ressource |w (DE-627)KFL000006386 |w (DE-600)2099324-9 |w (DE-576)273874209 |x 1873-5576 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2019 |g number:9 |g pages:756- |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/bentham-ejournals-pharmazie/www.eurekaselect.com/openurl/content.php?genre=article&issn=1568-0096&volume=19&issue=9&spage=756 |m X:KFL |x Verlag |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-BEJ | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 935 | |i IMPORT_0628_prod_DARH_02 | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2019 |e 9 |h 756- | ||